Dive into the complex landscape of immune checkpoint inhibitors (ICIs) in lung cancer in our poster presentation.
As the use of immunotherapy in early-stage non-small cell lung cancer (NSCLC) remains a challenge, we offer a spatially-informed approach to identify useful biomarkers. By using spatial biomarker assays, and analysis involving spatial transcriptomics and proteomics, we reveal the cell-to-cell interactions in the tumor microenvironment.
Download our poster to explore our findings and gain insights into the suitability of ICIs for personalized therapy